AtaiBeckley
AtaiBeckley is a clinical-stage biopharmaceutical company developing psychedelic-based neuroplastogens, led by BPL-003 (intranasal 5-MeO-DMT with FDA Breakthrough Therapy designation), VLS-01 (buccal DMT film), and EMP-01 (oral R-MDMA), targeting treatment-resistant depression, social anxiety disorder, and opioid use disorder.
- Company typePublic
- Founded2018
- HeadquartersBerlin, Germany
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What AtaiBeckley does
AtaiBeckley is a clinical-stage biopharmaceutical company formed in November 2025 through the all-share combination of atai Life Sciences and Beckley Psytech, headquartered in New York and incorporated in Delaware following a December 2025 redomiciliation from the Netherlands. The company develops psychedelic-based neuroplastogens targeting mental health indications with significant unmet need, primarily treatment-resistant depression (TRD) and social anxiety disorder (SAD), with an earlier discovery program in opioid use disorder. Its lead asset, BPL-003, is a proprietary intranasal formulation of mebufotenin benzoate (5-MeO-DMT) granted FDA Breakthrough Therapy designation in October 2025, designed to produce rapid and durable antidepressant effects from a single dose within a two-hour interventional psychiatry paradigm; a Phase 3 ReConnection program is planned to initiate in Q2 2026 with topline data targeted for early 2029. The pipeline also includes VLS-01, a buccal film formulation of DMT for TRD in Phase 2, and EMP-01, an oral R-MDMA formulation for SAD that reported positive Phase 2a data in February 2026.
The company is pre-revenue from product sales, with Q1 2026 revenue of approximately $954,000 reflecting collaboration or grant receipts and operating cash burn of roughly $101.6 million per quarter. Capital sources include a $149.5 million public offering (October 2025), an up to $175 million term loan facility with Hercules Capital, and an up to $11.4 million NIDA grant. Management has publicly engaged Jefferies and JPMorgan to explore strategic options for BPL-003, including a potential sale or partnership targeting $2 billion or more. The product economics under discussion assume a projected net annual price of approximately $30,000 for BPL-003 at launch around 2030, with peak unadjusted US sales forecasts of $3.7 billion for BPL-003 and $2.6 billion for VLS-01 in 2036. Distribution is expected to occur through clinical settings with healthcare professional administration, and the company is investing in patient advocacy, including a multi-year collaboration with PsyPAN, to shape interventional psychiatry delivery models ahead of commercialization.
AtaiBeckley firmographics
Firmographics- Name
- AtaiBeckley
- Legal name
- AtaiBeckley Inc.
- Website
- https://www.ataibeckley.com
- Company type
- Public
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- AtaiBeckley is a clinical-stage biopharmaceutical company developing psychedelic-based neuroplastogens, led by BPL-003 (intranasal 5-MeO-DMT with FDA Breakthrough Therapy designation), VLS-01 (buccal DMT film), and EMP-01 (oral R-MDMA), targeting treatment-resistant depression, social anxiety disorder, and opioid use disorder.
- Ownership category
- akta.pro rank
AtaiBeckley industry classification
Industry- Product category
- Clinical-stage psychedelic mental health therapeutics
- NAICS
- Medicinal and Botanical Manufacturing (325411)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where AtaiBeckley is headquartered
LocationHeadquarters
- HQ city
- Berlin
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
AtaiBeckley business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Pre-revenue clinical-stage company. Expected to commercialize BPL-003, VLS-01, and EMP-01 upon regulatory approval. Pricing model projects net annual price of $30,000 for BPL-003 at launch with peak unadjusted U.S. sales of $3.7 billion for BPL-003 and $2.6 billion for VLS-01 in 2036.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Projected net annual price for BPL-003 at launch |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
AtaiBeckley product offering
Product offeringCore offering
AtaiBeckley is a clinical-stage biopharmaceutical company developing proprietary psychedelic-based neuroplastogen therapies for mental health conditions with significant unmet need. Its pipeline includes intranasal mebufotenin benzoate (BPL-003), buccal DMT film (VLS-01), oral R-MDMA (EMP-01), and an early-stage program targeting novel 5-HT2A receptor agonists, all designed to deliver rapid, durable treatment effects within a two-hour interventional psychiatry paradigm.
Product overview
AtaiBeckley is a clinical-stage biopharmaceutical company formed in 2025 through the strategic combination of atai Life Sciences and Beckley Psytech. The company operates as a unified platform developing a portfolio of psychedelic-based neuroplastogens for mental health conditions. Its core product pipeline includes: BPL-003 (mebufotenin benzoate intranasal formulation for treatment-resistant depression in Phase 2), VLS-01 (DMT buccal film for treatment-resistant depression in Phase 2), EMP-01 (oral R-MDMA for social anxiety disorder in Phase 2), and a Discovery program developing novel 5-HT2A receptor agonists including non-hallucinogenic compounds for opioid use disorder and TRD. All lead products are designed to produce rapid, robust, and durable treatment effects within a two-hour interventional psychiatry treatment paradigm.
Differentiator
Problem solved
Functional benefit
Products and services
- BPL-003 (Mebufotenin Benzoate) A proprietary synthetic intranasal formulation of mebufotenin benzoate (5-MeO-DMT) being developed as a rapid-acting, durable treatment for treatment-resistant depression, designed for administration within a two-hour interventional psychiatry treatment paradigm with FDA Breakthrough Therapy designation.
- VLS-01 (Buccal Film DMT)
Quantifiable outcome
- 66.7% response rate at Day 2 among treatment-resistant depression patients receiving single dose of BPL-003
- +5 more outcomes
Companies that use AtaiBeckley
Customer profileSegments2 records
Ideal customer profiles2 records
AtaiBeckley technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
AtaiBeckley partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and core.
- PsileraminorStrategic licensing agreement with Psilera for DMT patent portfolio, along with up to $2 million in NIH funding support for Psilera's neuroplastogen PSIL-006 development. Positions Psilera to transition from discovery-stage to clinical-stage organization.
- Psychedelic Participant Advocacy Network (PsyPAN)coreMulti-year collaboration on participant-informed psychedelic clinical research including qualitative workshops, published white paper titled 'The Participants in Their Own Words,' and 12-month independent peer-support pilot program for UK participants. Expanded to include international patient advocacy organizations and academic collaborators at King's College London and University of Exeter.
- Beckley Psytech LimitedcoreStrategic combination of atai Life Sciences and Beckley Psytech completed on November 5, 2025, forming AtaiBeckley as a global leader in psychedelic mental health therapies. Combined pipeline includes BPL-003, VLS-01, and EMP-01 across treatment-resistant depression and social anxiety disorder indications.
Scale indicators10 records
Recent moves8 records
Expansion highlights6 records
AtaiBeckley competitors and assessment
Company assessmentDirect peers
- GH Research: Clinical-stage biopharmaceutical company developing mebufotenin (5-MeO-DMT) therapies for treatment-resistant depression, the same molecular target and indication as AtaiBeckley's BPL-003, making it the most direct head-to-head competitor in the psychedelic CNS space.
- Compass Pathways: Clinical-stage company developing psilocybin therapy (COMP360) for treatment-resistant depression, with Phase 3 programs underway. Direct competitor in psychedelic therapeutics for TRD, with overlapping patient population and clinical development strategy.
- MindMed: Clinical-stage psychedelic medicine biotech developing lysergic acid diethylamide (LSD) and MDMA-based therapies for anxiety, depression, and ADHD. Comparable pipeline of psychedelic-based neuroplastogens targeting CNS indications with similar clinical-stage risk profile.
- Cybin: Clinical-stage psychedelics company developing proprietary deuterated psilocybin analog (CYB003) for major depressive disorder and other CNS indications. Comparable psychedelic biotech with overlapping clinical-stage programs in depression.
Broad incumbents
- Axsome Therapeutics: Commercial-stage CNS specialty biopharma with Auvelity (dextromethorphan/bupropion) approved for major depressive disorder. Comparable CNS specialty pharma with overlapping depression indication, though with established commercial revenue and a non-psychedelic mechanism.
- Sage Therapeutics: CNS-focused biopharmaceutical company with Zurzuvae (zuranolone) approved for postpartum depression, a neuroactive steroid with rapid-onset antidepressant properties. Comparable CNS specialty pharma targeting depression with differentiated non-psychedelic mechanism.
- Johnson & Johnson: Large pharmaceutical company with Spravato (esketamine) approved for treatment-resistant depression, the first FDA-approved rapid-acting antidepressant with a psychedelic-adjacent mechanism. Most directly relevant commercial-stage competitor in the interventional psychiatry treatment paradigm.
- Eli Lilly: Major pharmaceutical company with extensive CNS/depression portfolio including fluoxetine (Prozac) and active development of next-generation antidepressants. Relevant incumbent with deep CNS expertise and large commercial infrastructure that could compete with or potentially acquire psychedelic assets.
Emerging players
- Seelos Therapeutics: Clinical-stage biopharmaceutical company developing psychedelic-based therapies (SLS-002 intranasal racemic ketamine) for suicidality and other CNS indications. Comparable smaller psychedelic biotech with adjacent interventional psychiatry focus.
- Neumora Therapeutics: Clinical-stage CNS biopharma developing novel therapeutics for depression and other brain disorders, with pipeline assets including NMRA-140 (M4 muscarinic agonist) for schizophrenia. Comparable clinical-stage CNS biotech targeting high-unmet-need psychiatric indications.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
AtaiBeckley social profiles
Digital presenceAtaiBeckley financial estimates
Financial estimateRevenue estimate
Valuation estimate
AtaiBeckley leadership team
Management profileNumber of profiles
Profiles16 records
AtaiBeckley subsidiaries and ownership
Company hierarchySubsidiaries1 record
AtaiBeckley funding detail
Funding detailFunding overview
Funding rounds14 records
Investors45 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AtaiBeckley M&A and investment
M&A and investmentM&A6 records
Investments19 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AtaiBeckley
What does AtaiBeckley do?
AtaiBeckley is a clinical-stage biopharmaceutical company developing proprietary psychedelic-based neuroplastogen therapies for mental health conditions with significant unmet need. Its pipeline includes intranasal mebufotenin benzoate (BPL-003), buccal DMT film (VLS-01), oral R-MDMA (EMP-01), and an early-stage program targeting novel 5-HT2A receptor agonists, all designed to deliver rapid, durable treatment effects within a two-hour interventional psychiatry paradigm.
Is AtaiBeckley a public or private company?
AtaiBeckley is a public company. It is classified as public and is currently operating.
When was AtaiBeckley founded?
AtaiBeckley was founded in 2018. It employs 101 to 250 people.
Where is AtaiBeckley based?
AtaiBeckley is headquartered in Berlin, Germany, in the Europe region.
How does AtaiBeckley make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are AtaiBeckley's main competitors?
Direct peers on record are GH Research, Compass Pathways, MindMed and Cybin. Broad incumbents are Axsome Therapeutics, Sage Therapeutics, Johnson & Johnson and Eli Lilly. Emerging players are Seelos Therapeutics and Neumora Therapeutics.
Does AtaiBeckley have an API?
No public API is recorded for AtaiBeckley.
What industry is AtaiBeckley in?
AtaiBeckley's product category is Clinical-stage psychedelic mental health therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325411 and its SIC code is 2833.